MK-677 vs Ipamorelin: Oral vs Injectable GH

MK-677 is a non-peptide, orally active ghrelin mimetic originally developed by Merck. It binds the ghrelin receptor (GHS-R1a) and stimulates growth hormone release from the pituitary gland. A single 25 mg oral dose sustains elevated GH and IGF-1 for a full 24 hours.

It is not a peptide. It is not a SARM, despite frequent mislabeling on supplement websites. MK-677 is a small molecule with oral bioavailability above 60% (Murphy et al., J Clin Endocrinol Metab, 1998).

In healthy elderly subjects, 25 mg/day for 4 weeks restored IGF-1 levels to the range of young adults, a 40-60% increase from baseline (Chapman et al., J Clin Endocrinol Metab, 1996). A 12-month randomized controlled trial confirmed sustained fat-free mass increases but documented insulin resistance as the primary safety concern (Nass et al., 2008).

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that earned the title "first selective growth hormone secretagogue" in the landmark Raun et al. study. It stimulates GH release through the ghrelin receptor, but with a selectivity profile unlike any other compound in its class.

At doses up to 200 times the effective threshold, ipamorelin does not elevate cortisol, ACTH, prolactin, FSH, LH, or TSH (Raun et al., Endocrinology, 1998). No other GH secretagogue achieves this level of selectivity. This is not marketing language; it is the defining result of a preclinical study that distinguished ipamorelin from every compound that came before it.

Its half-life is approximately 2 hours, with a GH peak at about 40 minutes post-injection and dose-proportional pharmacokinetics (Johansen et al., Eur J Clin Pharmacol, 1999). Standard dosing is 100-300 mcg subcutaneously, typically paired with CJC-1295 for synergistic GHRH-GHRP activation.

Both compounds target the ghrelin receptor on the pituitary gland. The difference lies in activation pattern, duration, and downstream effects.

Both compounds raise GH and IGF-1 meaningfully. The pattern and duration differ.

MK-677 at 25 mg/day restored IGF-1 in elderly subjects to levels matching young adults (40-60% increase from baseline) within 2 weeks. After 12 months of continuous use, IGF-1 remained elevated and fat-free mass increased significantly by DXA scan (Nass et al., 2008). In obese subjects, 2 months of MK-677 increased fat-free mass and basal energy expenditure (Murphy et al., 1998).

Ipamorelin produces dose-proportional GH peaks at approximately 40 minutes post-injection. The GH pulse is sharp and resolves within 4-6 hours. Direct body composition studies for ipamorelin alone are limited; most clinical data uses ipamorelin combined with CJC-1295.

This is where the two compounds diverge most sharply. MK-677 carries metabolic risks that ipamorelin does not.

Both compounds are commonly used for sleep improvement. MK-677 has a specific advantage here.

Copinschi et al. (1997) administered MK-677 to young men and documented a 50% increase in Stage IV (deep) sleep duration and a 20% increase in REM sleep. Total sleep time did not change, but the quality shifted toward more restorative stages (Copinschi et al., Neuroendocrinology, 1997).

Ipamorelin lacks a dedicated sleep study. Users commonly report improved sleep quality, deeper rest, and vivid dreams, consistent with GH-mediated sleep enhancement. The mechanism is sound: GH secretion naturally peaks during deep sleep, and ipamorelin before bed amplifies this pulse.

For documented sleep enhancement, MK-677 has stronger published evidence. For sleep improvement without metabolic risk, ipamorelin before bed is the conservative choice. For a broader review of sleep-targeting peptides, see our peptides for sleep guide.

MK-677 has the most direct body composition evidence among non-prescription GH secretagogues.

The Nass 2008 twelve-month study used DXA in healthy elderly subjects. MK-677 at 25 mg/day produced statistically significant increases in fat-free mass. Limb fat also increased. Total body weight rose, partly from water retention and lean tissue. Grip strength and physical function did not improve despite the body composition changes.

In obese subjects, Murphy et al. (1998) documented increased fat-free mass and basal metabolic rate after 2 months. Higher lean mass combined with higher energy expenditure is favorable for recomposition, though insulin resistance complicates long-term use.

Ipamorelin standalone body composition data is limited. The CJC-1295/ipamorelin combination is the standard clinical protocol, and practitioners report improvements in fat loss, recovery, and lean tissue over 8-12 week cycles. For a broader comparison including FDA-approved options for fat loss, see best peptides for weight loss.

MK-677 is cheaper and more convenient. This explains its popularity despite the metabolic risks.

MK-677 requires zero injection supplies and no reconstitution. For people with needle aversion, this is a decisive advantage. Ipamorelin requires purchasing bacteriostatic water, insulin syringes, and the peptide vial, then reconstituting and injecting subcutaneously 1-3 times daily. Use our peptide reconstitution calculator for guidance on ipamorelin preparation.

Both compounds are research chemicals without FDA approval. MK-677 is sometimes mislabeled and sold as a dietary supplement. The FDA has issued warnings against such products. Ipamorelin is available through compounding pharmacies with a valid prescription.

The decision framework is clear once you weigh metabolic risk against convenience.

Stacking MK-677 with ipamorelin is not recommended. Both target the ghrelin receptor, creating pharmacological redundancy rather than synergy. You double the ghrelin pathway stimulation without adding a complementary mechanism.

Additive appetite stimulation and water retention would be pronounced. Insulin resistance risk from MK-677 would persist regardless of stacking.

Better stacks activate two distinct receptor pathways. Ipamorelin pairs with CJC-1295 (a GHRH analog that activates the GHRH receptor) for genuine synergy: the GHRH analog tells the pituitary to produce GH, while ipamorelin tells it to release GH. MK-677 is best used alone. For comprehensive stacking guidance, see our peptide stacking guide.

Both compounds require monitoring, but MK-677 demands more frequent glucose checks.

Stop MK-677 immediately if: fasting glucose exceeds 126 mg/dL on two consecutive readings, fasting insulin doubles from baseline, or lower extremity edema develops and does not resolve with hydration and sodium reduction.

Stop ipamorelin if: severe persistent headaches develop, joint pain limits daily function, or IGF-1 exceeds the upper reference range for your age. For comprehensive safety protocols, see our peptide safety guide.

Neither MK-677 nor ipamorelin is FDA-approved for any indication. All human data comes from Phase I/II clinical trials and observational reports.

MK-677 carries specific risks that cannot be understated. A randomized trial in elderly hip fracture patients was stopped early because MK-677 subjects showed signs of congestive heart failure. The glucose and insulin sensitivity effects are documented across multiple studies and are not theoretical.

Do not use MK-677 if you have type 2 diabetes, prediabetes, or poorly controlled fasting glucose. Do not use either compound if you have active cancer or a history of hormone-sensitive cancers without oncologist clearance. IGF-1 elevation may theoretically promote tumor growth.

For recovery-focused peptide comparisons, see our peptides for recovery guide. For muscle growth context, see peptides for muscle growth.